Original Article

Gene Therapy (2010) 17, 846–858; doi:10.1038/gt.2010.26; published online 15 April 2010

Meganucleases can restore the reading frame of a mutated dystrophin

P Chapdelaine1, C Pichavant1, J Rousseau1, F Pâques2 and J P Tremblay1

  1. 1CHUL, Centre de Recherche du CHUQ, Québec, Canada
  2. 2Cellectis S.A., Cellectis Genome Surgery, Romainville, France

Correspondence: Dr JP Tremblay, Human Genetic, Unite de Recherche en Gentique Humaine, Centre de Recherche du CHUL, 2705 boulevard Laurier, Ste-Foy, Québec G1V 4G2, Canada. E-mail: jacques-p.tremblay@crchul.ulaval.ca

Received 15 October 2009; Revised 5 January 2010; Accepted 6 January 2010; Published online 15 April 2010.



Mutations in Duchenne muscular dystrophy (DMD) are either inducing a nonsense codon or a frameshift. Meganucleases (MGNs) can be engineered to induce double-strand breaks (DSBs) at specific DNA sequences. These breaks are repaired by homologous recombination or by non-homologous end joining (NHEJ), which results in insertions or deletions (indels) of a few base pairs. To verify whether MGNs could be used to restore the normal reading frame of a dystrophin gene with a frameshift mutation, we inserted in a plasmid coding for the dog μ-dystrophin sequences containing a MGN target. The number of base pairs in these inserted sequences changed the reading frame. One of these modified target μ-dystrophin plasmids and an appropriate MGN were then transfected in 293FT cells. The MGN induced micro-deletion or micro-insertion in the μ-dystrophin that restored dystrophin expression. MGNs also restored μ-dystrophin expression in myoblasts in vitro and in muscle fibers in vivo. The mutation of the targeted μ-dystrophin was confirmed by PCR amplification followed by digestion with the Surveyor enzyme and by cloning and sequencing of the amplicons. These experiments are thus a proof of principle that MGNs that are adequately engineered to target appropriate sequences in the human dystrophin gene should be able to restore the normal reading frame of that gene in DMD patients with an out-of-frame deletion. New MGNs engineered to target a sequence including or near nonsense mutation could also be used to delete it.


meganuclease; Duchenne muscular dystrophy; gene correction; reading frame correction; dystrophin